

PATENT APPLICATION
ATTORNEY DÖÖKET XX: 27866/34810

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	 I hereby certify that this paper is being deposited with the United States Postal Service as First
Patrick Gray et al.) Class mail, postage prepaid, in an envelope) addressed to: Commissioner for Patents,
Serial No: 09/509,165	Washington, D.C. 20231 on February 25, 2002. RECEIVED
Filed: June 12, 2000	
For: Macrophage Derived Chemokine (MDC), MDC Analogs, MDC Inhibitor Substances, and Uses Thereof	MAR 12 2002 Sharon M. Sintich MAR 12 2002
Art Unit: 1648	Registration No. 48,484 Agent for Applicants
Examiner: B. Li)

AMENDMENT IN RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents Washington, DC 20231

Sir:

This is in response to a "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed January 23, 2002 (copy enclosed herewith). The Patent Office indicated that the above-identified application failed to comply with one or more of the requirements of 37 C.F.R. §§ 1.821-1.825, pertaining to Sequence Listings. The applicants request entry of the following amendments to correct the Sequence Listing.